Immunization, measles second dose in Middle income
Middle income: Immunization, measles second dose was 80.1% in 2024. ▲ Rising
Immunization, measles second dose in Middle income, 2000–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children by the nationally recommended age.
Analysis
Middle income recorded 80.1% for immunization, measles second dose in 2024. That is the highest value across all 25 years on record.
That represents a change of up 2.1% on the previous year and up 28.5% over ten years.
Over the whole period, immunization, measles second dose in Middle income peaked at 80.1% in 2024 and was at its lowest, 14.3%, in 2000.
That places Middle income 21st out of 43 groups with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently rising across the 25 years of available data.
Immunization, measles second dose in Middle income, year by year
| Year | % of children by the nationally recommended age | Change |
|---|---|---|
| 2000 | 14.3% | — |
| 2001 | 16.2% | +13.1% |
| 2002 | 15.7% | -3.4% |
| 2003 | 16.7% | +6.4% |
| 2004 | 17.6% | +5.7% |
| 2005 | 31.4% | +78.5% |
| 2006 | 34.0% | +8.4% |
| 2007 | 35.1% | +3.1% |
| 2008 | 36.9% | +5.0% |
| 2009 | 40.3% | +9.4% |
| 2010 | 41.4% | +2.7% |
| 2011 | 50.3% | +21.4% |
| 2012 | 54.3% | +7.9% |
| 2013 | 59.2% | +9.0% |
| 2014 | 62.3% | +5.3% |
| 2015 | 66.4% | +6.6% |
| 2016 | 71.4% | +7.5% |
| 2017 | 72.7% | +1.9% |
| 2018 | 74.7% | +2.7% |
| 2019 | 75.2% | +0.6% |
| 2020 | 76.0% | +1.1% |
| 2021 | 75.1% | -1.1% |
| 2022 | 78.4% | +4.3% |
| 2023 | 78.4% | +0.0% |
| 2024 | 80.1% | +2.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 25.8% | 14.3% | 40.3% | 10 |
| 2010s | 62.8% | 41.4% | 75.2% | 10 |
| 2020s | 77.6% | 75.1% | 80.1% | 5 |
Countries ranked near Middle income
More health data for Middle income
- Population ages 30-34, male, per capita 0.0385 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 2.22 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0387 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.76 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0371 units per person (2025)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, female, annual growth rate 1.55 % change on previous year (2025)
- Population ages 25-29, male, per capita 0.0386 units per person (2025)
Frequently asked questions
- What is immunization, measles second dose in Middle income?
- Immunization, measles second dose in Middle income was 80.1% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, measles second dose recorded in Middle income?
- The highest recorded value was 80.1% in 2024.
- What is the lowest immunization, measles second dose recorded in Middle income?
- The lowest recorded value was 14.3% in 2000.
- How does Middle income rank for immunization, measles second dose?
- Middle income ranks 21st out of 43 groups with data for 2024.
- Is immunization, measles second dose rising or falling in Middle income?
- Over the last ten years it is up 28.5%. The long-run trend across the full record is rising.
- Where does this Middle income data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, measles second dose (% of children by the nationally recommended age). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, measles second dose, measures the percentage of children who received two dose of measles containing vaccine according to nationally recommended schedule through routine immunization services in a given year.